First U.S. patients could receive H1N1 vaccine next week

NewsGuard 100/100 Score

U.S. health officials announced Thursday the first batches of the H1N1 (swine flu) vaccine the government ordered will begin arriving in designated locations across the country on Tuesday and may be administered in the first patients by the end of next week, Reuters reports (Fox, 10/1).

The kick-off of the massive vaccination campaign will be challenging for U.S. health officials, USA Today reports. "In a task worthy of a deadly serious video game, state health departments have to organize thousands of workers at 90,000 sites nationwide to administer as many as 250 million doses in three to four months, making sure the people at greatest risk from swine flu — such as pregnant women, young children and health care workers — are first in line. On top of the logistics, health officials have to convince a somewhat skeptical public that swine flu vaccinations are necessary" (Weise, 10/1).

The CDC also issued a report Thursday that showed the impact of H1N1 on pregnant women, the Washington Post reports. The findings showed "100 pregnant women infected with the virus were hospitalized in intensive care units in the first four months of the outbreak," and 28 died within the first four months of the outbreak (Brown, 10/2). CQ HealthBeat reports that Anne Schuchat, a physician at the CDC, emphasized the importance for pregnant women to protect themselves against the H1N1 virus by receiving the vaccine (Reichard, 10/1).

Another study, released Thursday, shows how a second wave of the H1N1 flu could overwhelm hospitals and health departments in the U.S., Reuters reports in a second story. "The study, based on estimates from a computer model developed by the" CDC found "[f]ifteen states could run out of hospital beds and 12 more could fill 75 percent of their beds with swine flu sufferers if 35 percent of Americans catch the virus in coming weeks," the news service writes (Steenhuysen, 10/1).

Pandemic Can Guide Future Preparedness, Vaccine Development, Researchers Say

In related news, Bloomberg examines the ways the H1N1 pandemic may guide the development of a universal flu vaccine and improve worldwide emergency preparedness, as researchers describe in the journal Science.

"Preparations for the pandemic have already helped more than double worldwide vaccine manufacturing capacity to 900 million doses from 400 million, the scientists from Novartis AG, the U.S. National Institutes of Health, Erasmus University and the World Health Organization said in the article," Bloomberg writes, noting efforts currently underway to develop vaccines that protect against the majority of flu strains.

"'Although the H1N1 pandemic has the potential to cause a social and economic emergency, it also provides an opportunity to rethink our approach to influenza virus disease and to develop more effective vaccines and economically sustainable solutions for developing and developed countries,' researchers led by Rino Rappuoli of Novartis Vaccines and Diagnostics Srl wrote in the report," the news service writes. The report also indicated the need for developing countries to improve influenza surveillance and incorporate flu vaccines into childhood immunization programs (Gerlin, 10/1).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
ChatGPT could be an effective tool to help reduce vaccine hesitancy